Browsing ICR Divisions by title
Now showing items 3736-3755 of 4660
-
Roles of cancer associated fibroblasts in squamous cell carcinoma
(Institute of Cancer Research (University Of London), 2021-03-31)Cancer associated fibroblasts (CAFs) play a key role in the tumour microenvironment (TME) of squamous cell carcinoma. Influenced by cues from cancer cells, CAFS remodel the extracellular matrix and secrete cytokines and ... -
Roles of Elongator Dependent tRNA Modification Pathways in Neurodegeneration and Cancer.
(MDPI, 2018-12-28)Transfer RNA (tRNA) is subject to a multitude of posttranscriptional modifications which can profoundly impact its functionality as the essential adaptor molecule in messenger RNA (mRNA) translation. Therefore, dynamic ... -
RORγt+ Innate Lymphoid Cells Promote Lymph Node Metastasis of Breast Cancers.
(AMER ASSOC CANCER RESEARCH, 2017-03-01)Cancer cells tend to metastasize first to tumor-draining lymph nodes, but the mechanisms mediating cancer cell invasion into the lymphatic vasculature remain little understood. Here, we show that in the human breast tumor ... -
ROS Dynamics Delineate Functional States of Hippocampal Neural Stem Cells and Link to Their Activity-Dependent Exit from Quiescence.
(CELL PRESS, 2021-02-04)Cellular redox states regulate the balance between stem cell maintenance and activation. Increased levels of intracellular reactive oxygen species (ROS) are linked to proliferation and lineage specification. In contrast ... -
RPAP3 provides a flexible scaffold for coupling HSP90 to the human R2TP co-chaperone complex.
(Springer Science and Business Media LLC, 2018-04-16)The R2TP/Prefoldin-like co-chaperone, in concert with HSP90, facilitates assembly and cellular stability of RNA polymerase II, and complexes of PI3-kinase-like kinases such as mTOR. However, the mechanism by which this ... -
rs2735383, located at a microRNA binding site in the 3'UTR of NBS1, is not associated with breast cancer risk.
(NATURE PORTFOLIO, 2016-11-15)NBS1, also known as NBN, plays an important role in maintaining genomic stability. Interestingly, rs2735383 G > C, located in a microRNA binding site in the 3'-untranslated region (UTR) of NBS1, was shown to be associated ... -
RTT-led IGRT for cervix cancer; training, implementation and validation.
(Elsevier BV, 2019-12-16)INTRODUCTION: IGRT in cervical cancer treatment delivery is complex due to significant target and organs at risk (OAR) motion. Implementing image assessment of soft-tissue target and OAR position to improve accuracy is ... -
Runs of homozygosity and testicular cancer risk.
(WILEY, 2019-07-01)BACKGROUND: Testicular germ cell tumour (TGCT) is highly heritable but > 50% of the genetic risk remains unexplained. Epidemiological observation of greater relative risk to brothers of men with TGCT compared to sons has ... -
Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial.
(LIPPINCOTT WILLIAMS & WILKINS, 2023-07-01)PURPOSE: Polycythemia vera (PV) is characterized by JAK/STAT activation, thrombotic/hemorrhagic events, systemic symptoms, and disease transformation. In high-risk PV, ruxolitinib controls blood counts and improves symptoms. ... -
Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial.
(NATURE PORTFOLIO, 2023-07-25)All antibodies approved for cancer therapy are monoclonal IgGs but the biology of IgE, supported by comparative preclinical data, offers the potential for enhanced effector cell potency. Here we report a Phase I dose ... -
Safety and Efficacy of Atezolizumab in Understudied Populations with Pretreated Urinary Tract Carcinoma: Subgroup Analyses of the SAUL Study in Real-World Practice.
(LIPPINCOTT WILLIAMS & WILKINS, 2021-08-01)PURPOSE: Atezolizumab is an established treatment option for pretreated urothelial carcinoma, demonstrating efficacy in phase II/III trials. The SAUL study enrolled a broader patient population to determine safety and ... -
Safety and efficacy of cobimetinib plus atezolizumab in patients with solid tumors: a phase II, open-label, multicenter, multicohort study.
(ELSEVIER, 2023-04-01)BACKGROUND: Although introduction of immune checkpoint inhibitors has revolutionized the treatment of cancer, their response rates are generally low. Preclinical and early phase clinical data suggest that MEK inhibition ... -
Safety and efficacy of durvalumab with R-CHOP or R<sup>2</sup>-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial.
(2021-11-19)Patients with high-risk diffuse large B-cell lymphoma (DLBCL) have poor outcomes following first-line cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab (R-CHOP). Evidence shows chemotherapy and immune ... -
Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses.
(2019-08-13)Background PALETTE is a phase 3 trial that demonstrated single-agent activity of pazopanib in advanced soft tissue sarcomas (aSTS). We performed retrospective subgroup analyses to explore potential relationships between ... -
Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma.
(AMER SOC HEMATOLOGY, 2016-07-28)Patients with relapsed and/or refractory multiple myeloma (RRMM) have poor prognosis. The STRATUS study assessed safety and efficacy of pomalidomide plus low-dose dexamethasone in the largest cohort to date of patients ... -
Safety and efficacy of T-DM1 in 128 patients with advanced HER2+breast cancer: The Royal Marsden experience
(OXFORD UNIV PRESS, 2019-10-01) -
Safety and efficacy of T-DM1 in patients with advanced HER2-positive breast cancer The Royal Marsden experience.
(Elsevier BV, 2020-01-01)BACKGROUND: Ado-trastuzumab emtansine (T-DM1) is standard of care for patients with advanced HER2+ breast cancer who relapse within 6 months of adjuvant trastuzumab or progress on first-line anti-HER2 therapy. We evaluated ... -
Safety and Feasibility of Surgery for Oropharyngeal Cancers During the SARS-CoV-2-Pandemic.
(FRONTIERS MEDIA SA, 2021-03-24)